Alamar Biosciences partners with Abcam to drive understanding of the human proteome

05 January 2022 | Wednesday | News

Alamar selects Abcam as a key provider of antibody content for its propriety NULISA technology platform
Image Source : Public Domain

Image Source : Public Domain

 Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of the human proteome.

The field of proteomic analysis is in the spotlight.  Its advance not only enhances the understanding of fundamental biology, but also sheds light on the status of human health and disease. A deeper understanding of the proteome is set to play a crucial role in enabling the next wave of innovations in research, diagnostics and therapeutics. Powering this effort requires new technology platforms that are able to address the two essential goals in proteomic analysis, namely the ability to go as deeply as possible to detect very low abundance proteins and the ability to profile thousands of proteins in a single sample.

Dr. Yuling Luo, Founder & CEO of Alamar, commented"Alamar is working to enable the early detection of cancer and other diseases by simultaneous measurement of hundreds to thousands of targets, even those present in minute amounts. We are very happy to partner with Abcam to access their extensive portfolio of recombinant monoclonal antibody pairs, which will accelerate our ability to bring our proteomic discovery tools to researchers."

"We are excited to be partnering with Alamar as they develop an automated proteomics platform that has the potential to offer unprecedented combination of sensitivity, plex-level and dynamic range," commented Dr Emma Sceats, SVP Sales, Service and Business Development at Abcam"The NULISA technology platform will provide an important tool for life science research, pharmaceutical development and diagnostics, enhancing understanding of the circulating proteome and supporting low abundance biomarker discovery. Such capability will be critical for the discovery and measurement of many proteins in human plasma and other samples that are currently undetectable."

Abcam's portfolio of over 1,300 fit-for-purpose recombinant antibody pairs is actively curated to ensure that it is representative of the key disease areas of interest. Designed to enhance biomarker discovery and support deeper understanding of the circulating proteome, the portfolio has been pre-validated specifically for multiplex applications.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in